Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.66 |
| ▸ | WNT3A | P56704 | 3/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48702 | 0.88 | PIK3CG (0.61) | PIK3CDPIK3CAPIK3CGPIK3CBWNT3A | |
| SCHEMBL27597047 | 0.80 | PIK3CA (0.81) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL48857 | 0.80 | PIK3CG (1.00) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KB | |
| SCHEMBL48623 | 0.77 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KB | |
| SCHEMBL1725743 | 0.76 | WNT3A (1.00) | WNT3AMEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL48850 | 0.76 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KB | |
| SCHEMBL1784577 | 0.76 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KB | |
| SCHEMBL1786172 | 0.75 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CGPIK3CBPI4KB | |
| SCHEMBL48593 | 0.75 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CGPIK3CBALDH1A1 | |
| SCHEMBL7846410 | 0.75 | RORC (0.68) | PI4KBRORCMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | claimed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| CN-100548996-C | 5-phenylthiazole derivatives and their use for the preparation of medicaments | NOVARTIS AG (CH) | 2009-10-14 | — | — | CN | disclosed |
| CN-1639139-A | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CA 1/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.